Mark Prausnitz, Georgia Institute of Technology, Atlanta Georgia. USA
A number of transdermal drugs have been approved by FDA since scopolamine in 1979 -- now transdermal drug delivery is a multi-million industry around the world. The technology has evolved from conventional patches (first generation); to chemical enhancers, non-cavitational ultrasound, and iontophoresis (second generation); to a third generation of nano and micro delivery, a more aggressive approach to overcoming the barrier properties of the skin. This third generation makes delivery of a wider variety of drugs and substances possible.